Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

319
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
319
Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

2.3K
Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
2.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

512
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
512
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

783
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
783
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

337
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
337
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

338
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Thoracic endometriosis and lymphangioleiomyomatosis: Coincidence or hormonal rational?]

Revue des maladies respiratoires·2020
Same author

Tracheal obstruction due to tumour: use of veno-venous extracorporeal membrane oxygenation during rigid bronchoscopy.

Anaesthesia reports·2020
Same author

[Cerebral air embolism: A rare complication of flexible fiberoptic bronchoscopy].

Revue des maladies respiratoires·2020
Same author

Classic biphasic pulmonary blastoma: A case report and review of the literature.

Critical reviews in oncology/hematology·2018
Same author

[Evolution of pain during respiratory rehabilitation after major lung resection].

Revue des maladies respiratoires·2016
Same author

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Related Experiment Video

Updated: Oct 11, 2025

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica
03:32

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

Published on: April 12, 2019

8.1K

[Sodium valproate-induced pleural effusion: When it changes sides!]

M Agossou1, N Venissac2

  • 1Service de pneumologie, CHU de Martinique, route de Chateauboeuf, 97261 Fort-de-France, Martinique.

Revue Des Maladies Respiratoires
|December 7, 2021
PubMed
Summary
This summary is machine-generated.

Sodium valproate can cause pleural effusion, a rare side effect. This case highlights an atypical presentation years after treatment initiation, emphasizing the need for vigilance in diagnosing drug-induced conditions.

Keywords:
Drug-induced pleural effusionEosinophilic pleural effusionExudative pleural effusionPleural effusionPleurésie exsudativePleurésie médicamenteusePleurésie éosinophiliqueSodium valproateValproate de sodium

More Related Videos

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion
03:22

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion

Published on: November 10, 2023

978
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.6K

Related Experiment Videos

Last Updated: Oct 11, 2025

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica
03:32

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

Published on: April 12, 2019

8.1K
Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion
03:22

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion

Published on: November 10, 2023

978
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.6K

Area of Science:

  • Neurology
  • Pulmonology
  • Pharmacology

Background:

  • Sodium valproate is a widely used antiepileptic and mood-stabilizing drug.
  • Pleural effusion is a known, albeit uncommon, adverse effect of sodium valproate therapy.
  • Typically, this effusion presents as eosinophilic pleurisy within months of starting treatment.

Observation:

  • This report details a unique case of sodium valproate-induced pleural effusion.
  • The effusion manifested over 12 years after treatment initiation, deviating from the typical timeline.
  • The pleural fluid analysis revealed a non-eosinophilic, variegated cell profile.

Findings:

  • The patient experienced contralateral recurrence of pleural effusion despite continued sodium valproate treatment.
  • Discontinuation of sodium valproate led to complete resolution of the effusion.
  • A three-year follow-up confirmed the absence of recurrence after drug cessation.

Implications:

  • Sodium valproate-induced pleural effusion can exhibit atypical clinical and cytological features.
  • Delayed onset and non-eosinophilic presentations may lead to diagnostic challenges and misdiagnosis.
  • Awareness of these atypical presentations is crucial for timely diagnosis and appropriate management of drug-induced pleural effusions.